Learn what semaglutide is, how this GLP‑1 receptor agonist works in the pancreas, stomach, and brain, and why it’s transforming obesity, weight loss, and type 2 diabetes treatment with bariatric surgery–level results.
Discover how tirzepatide’s dual GIP/GLP‑1 receptor agonism is transforming peptide therapy for type 2 diabetes, delivering unprecedented HbA1c reductions, significant weight loss, and broader metabolic benefits compared to traditional GLP‑1 drugs.